US-based clinical-stage biotechnology company Calidi Biotherapeutics collaborates with National Institutes of Health on the therapeutic potential of oncolytic viruses delivered by mesenchymal stem cells.

US-based clinical-stage biotechnology company Calidi Biotherapeutics has announced an ongoing scientific collaboration with the Cell Therapy Section at the Department of Transfusion Medicine of National Institutes of Health’s (NIH).

The scientific collaboration will study the impact of different stem cell carriers on therapeutic potential of oncolytic viruses in cancer treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Currently, Calidi is developing a new immunotherapy method that utilises oncolytic vaccinia virus delivered through cell-based therapeutic platforms.

The company’s initial clinical trial using autologous cells to deliver the vaccinia virus showed good results of safety and efficacy in patients suffering with cancer.

The company is also developing off-the-shelf, allogeneic cell-based delivery technology to protect and potentiate the virus using cultured mesenchymal stem cells.

Calidi Biotherapeutics president for medical and scientific affairs Boris Minev said: “It has been an honor to work with the Department of Transfusion Medicine at the National Institutes of Health over the last ten months. This joint research is laying the groundwork for our future clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are driven by one mission; to create an affordable treatment that will eradicate cancer and save lives. As such, we are excited to participate with the NIH in the development of oncolytic virus-based therapies.  The ability to protect oncolytic viruses from destruction by the human immune system is very significant when it comes to developing the next generation of oncolytic immunotherapies.”

The collaboration will study how the natural immunomodulatory capacity would differ with the progression of oncolytic virus infection in the carrier stem cells.

The collaborative research will mainly analyse and compare the therapeutic potential of oncolytic viruses delivered by various different MSCs.